Evidence map›Paper›PMID 39524786›Full record

ArticleHeliyon2024

Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report.

Elia Morando, Lorenzo Losso, Massimo Carollo, Ilaria Costantini, Matilde Bacchion, Lucia Drezza, Giorgio Ricci

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elia MorandoUSD Poison Control Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Lorenzo LossoUSD Poison Control Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Massimo CarolloDepartment of Diagnostics and Public Health, University of Verona, Verona, Italy.
Ilaria CostantiniUSD Poison Control Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Matilde BacchionUSD Poison Control Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Lucia DrezzaUSD Poison Control Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Giorgio RicciUSD Poison Control Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for dabigatran, to reverse the anticoagulant effects of dabigatran and apixaban-induced coagulopathy. An 86-year-old patient, receiving apixaban therapy, presented to the Emergency Department after intentionally ingesting 50 tablets of dabigatran. The combination therapy contributed to the rapid normalization of coagulation parameters and stabilization of the patient's clinical status without subsequent thromboembolic complications. This case adds to the limited evidence on the effectiveness and safety of combining PCC with idarucizumab in cases of multiple anticoagulant intoxication.

Indexed as

Case reportDabigatranEmergency treatmentIdarucizumabPoison Control CentersProthrombin complex concentrates

Identifiers

PMID39524786
PMCPMC11547894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.